МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ
АКАДЕМИЧЕСКИХ НАУК
170
FEATURES ACCORDING TO THE ETIOLOGY OF OSTEOPOROSIS IN
CHRONIC HEART FAILURE
Nadirova Yulduz Isomovna
Jabbarov Ozimboy Otaxonovich
Tashkent Medical Academy, Tashkent, Uzbekistan
https://doi.org/10.5281/zenodo.15518513
Research objective.
A comparative assessment of some clinical aspects in
patients with chronic heart failure caused by ischemic heart disease against the
background of dilated cardiomyopathy , the cause of which has developed. This
is a pathological condition characterized by the destruction of bone tissue, and
the process of decay begins to prevail over synthesis. Against the background of
osteoporosis, the strength of bones decreases and, accordingly, their fragility
increases. In addition, there is a violation of the internal structure of bones.
Osteoporosis can be an independent pathology or serve as a symptom of other
diseases. Treatment of osteoporosis should be timely.
Material and methods.
The study involved 44 patients with signs of SYY,
with an average age of = 54.9 ± 14.1 (25 to 80) years. Depending on the etiology
of SYY, patients were divided into Group 2: Group 1 had 24 patients-DKMP and
Group 2 had 20 patients with Q - tooth myocardial infarction. Group 2 patients
underwent diagnostic coronary angiography before the examination. All
patients were given the following tests: general blood analysis; ECG; ExoKG; 6-
minute walk test and clinical case assessment using a shock scale. . The
difference of P<0.05 was considered reliable. Osteoporosis is one of the most
common diseases. Its prevalence is especially high among the elderly. Currently,
such a problem as osteoporosis is very relevant. Here are a few interesting facts:
• About eighty percent of women can be diagnosed with symptoms of this
pathology after an early age. It should be noted that this disease is much less
common in men.
• In European hospitals, the number of patients with osteoporosis after
forty-five years of age always significantly exceeds the number of patients with
myocardial infarction, breast cancer and diabetes mellitus.
• The most common complications are hip fracture, which affects 250,000
people in the United States each year.
• Almost every woman over 65 years old has at least one fracture, which is
often associated with osteoporosis.
• According to experts, if the spread of osteoporosis continues to grow as it
is now, after thirty years it can become a mass epidemic.
МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ
АКАДЕМИЧЕСКИХ НАУК
171
The signs and treatment of osteoporosis in women were common in ancient
times, evidence of which is the images of ancient times, in which people with a
characteristic pathology of the condition are depicted. European experts began
to deal closely with this problem only in the last century, when it was
discovered, according to which in old age it became known that a fracture of the
neck of the thigh was directly related to changes in bone tissue.
Research results
. The two groups were dominated by men: 17 (70.8%)
and 15 (75%) in Groups 1 and 2, respectively. Patients in Group 1 were
characterized by youth and a short period of illness (all p<0.05). No significant
differences were observed in scores on the shock scale, but Group 2 dominated
blood pressure indicators. The distance traveled during the 6-minute walk test
was found to be shorter in Group 2 patients and was accordingly characterized
by a higher functional class of SYY. It was probably associated with the
phenomenon of coronary vessel ischemia, as cardialgia complaints during the
test were the main complaints of individuals in Group 2 (25% and 13.64%
respectively). Conversely, shortness of breath and choking were more frequent
when Group 1 traveled relatively longer distances, while SAB and DAB grew
smaller at maximum physical load than Group 2. Evaluation of ExoKG
parameters showed that patients had smaller volumetric indicators of the left
parts of the 2nd Group heart (p>0.05), greater thickness of the heart muscle
walls (p>0.05), greater thickness of the heart muscle walls (p<0.05), and
correspondingly greater mass of the left ventricle myocardium. At the same
time, both groups have eccentric CHQ hypertrophy with cardiac dilation, with
CHQ of 2 in patients with YuIK at = 42.1 ± 15.9%, up 2.4% from Group 1.
Conclusion.
SYY, originating from yuik, is characterized by its development
for a much longer time and at an older age. Despite the relatively uniform
expansion of the heart cavities and decreased systolic function of the CHQ
myocardium, the phenomenon of remodeling is more typical for patients with
DKMP, which, according to ExoKG, has a clear dissociation between dilation and
CHQ myocardial hypertrophy. Treatment of the disease with medication
Hormone replacement therapy is used as a prophylaxis and in parallel with
other measures. It is recommended only at the initial stage of osteoporosis. At
the next stage of the development of the disease, a hormonal drug is used - an
analogue of the hormone secreted by the parathyroid glands. It Is Forsteo.
Literature:
1.
Mirzaeva, G. P., Yu, N., Buvamukhamedova, N. T., & Mukhiddinova, F. M.
(2023). Evaluation of the effectiveness of antioxidants on the functional state of
МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ
АКАДЕМИЧЕСКИХ НАУК
172
the kidneys in patients with diabetic nephropathy. The Journal of clinical
investigation, 12-23.
2.
Бобошарипов, Ф. Г., Холов, Х. А., Тешаев, О. Р., & Надирова, Ю. И.
(2023).
ПОСТБАРИАТРИЧЕСКАЯ
ГИПОГЛИКЕМИЯ
И
ГИПОТОНИЯ.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 21(5), 105-113.
3.
Надирова, Ю. И., Жаббаров, О. О., Бобошарипов, Ф. Г., Турсунова, Л. Д.,
& Мирзаева, Г. П. (2023). Оценка эффективности и оптимизация
дезаггрегантной терапии у больных с ИБС.
4.
Холов, Х. А., Тешаев, О. Р., Бобошарипов, Ф. Г., Амонуллаев, А. Х., &
Надирова, Ю. И. (2023). ОСТРЫЙ ПАНКРЕАТИТ-КАК НЕРЕШЕННАЯ
ПРОБЛЕМА МЕДИЦИНЫ. Академические исследования в современной
науке, 2(8), 192-206.
5.
Бобошарипов, Ф. Г., Холов, Х. А., Тешаев, О. Р., Алимов, С. У., &
Надирова, Ю. И. (2023). ОСЛОЖНЕНИЕ ОСТРОГО ХОЛЕЦИСТИТА У
БОЛЬНЫХ ПЕРЕНЯВШИСЬ COVID-19. In Международная конференция
академических наук (Vol. 2, No. 3, pp. 41-48).
6.
Бобошарипов, Ф. Г., Холов, Х. А., Тешаев, О. Р., Алимов, С. У., &
Надирова, Ю. И. (2023). КОМОРБИДНОЕ ТЕЧЕНИЕ ОСТРОГО ХОЛЕЦИСТИТА
У БОЛЬНЫХ COVID-19. Models and methods in modern science, 2(4), 51-58.
7.
Bobosharipov, F. G., Xolov, X. A., & Yu, N. (2024). ACUTE PANCREATITIS
AFTER ELECTIVE LAPAROSCOPIC CHOLECYSTECTOMY: RETROSPECTIVE
STUDY. In Proceedings of Scientific Conference on Multidisciplinary Studies (Vol.
3, No. 6, pp. 132-136).
8.
Bobosharipov, F. G., Ruxullayevich, T. O., Amonullayevich, X. X., &
Isomovna, N. Y. (2024). GENETIC INFLUENCES FOR PEPTIC ULCER DISEASE
ARE INDEPENDENT OF GENETIC FACTORS IMPORTANT FOR HP INFECTION.
9.
Надирова, Ю. И., & Бобошарипов, Ф. Г. (2024). Клинико-
диагностические аспекты раннего развития остеопороза при хронической
сердечной недостаточности.
10.
Бобошарипов, Ф. Г., Надирова, Ю. И., & Алимов, С. У. (2024).
ЛЕТАЛЬНОСТЬ ПОСЛЕ КОНСЕРВАТИВНОГО ЛЕЧЕНИЕ ПРИ ЯЗВЕННЫХ
ГАСТРОДУОДЕНАЛЬНЫХ КРОВОТЕЧЕНИЯХ.
11.
Надирова, Ю. И., Бобошарипов, Ф. Г., Кодирова, Ш. А., & Мирзаева, Г. П.
(2023). ОСТЕОПОРОЗ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. ОБРАЗОВАНИЕ
НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 21(5), 89-96.
МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ
АКАДЕМИЧЕСКИХ НАУК
173
12.
GP, M., OO, J., ZF, U., Sh I, Q., LD, T., Yu I, N., & AM, R. (2023). Assessment of
Efficacy and Optimization of Antiplatelet Therapy in Patients with Ischemic
Heart Disease.
13.
Надирова, Ю., & Жаббаров, О. (2023). ФАКТОРЫ РИСКА СНИЖЕНИЯ
ПРОЧНОСТИ КОСТИ И ПЕРЕЛОМОВ ПРИ ХБП.
14.
Надирова, Ю. И., & Нуриллаева, Н. М. (2019). РОЛЬ ГЕНЕТИЧЕСКОГО
ПОЛИМОРФИЗМА ГЕНА MTHFR C РИСКОМ РАЗВИТИЯ ИШЕМИЧЕСКОЙ
БОЛЕЗНИ СЕРДЦА. In Современная медицина: новые подходы и
актуальные исследования (pp. 20-23).
15.
Холов, Х. А., Бобошарипов, Ф. Г., & Надирова, Ю. И. К. (2016).
Оптимизация
диагностики
острого
панкреатита.
Биология
и
интегративная медицина, (6), 150-159.
16.
Nadirova, Y. (2024). SURUNKALI YURAK YETISHMOVCHILIGIDA
OSTEOPOROZ ETIOLOGIYASIGA KO ‘RA XUSUSIYATLARI. Инновационные
исследования в современном мире: теория и практика, 3(13), 35-38.
17.
Надирова, Ю. И., & Жаббаров, О. О. (2024). КОСТНАЯ ПАТОЛОГИЯ ПРИ
ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. Инновационные исследования в
современном мире: теория и практика, 3(13), 31-34.
18.
Bobosharipov, F. (2025). OSTEOPATHY IN CHRONIC KIDNEY DISEASE.
Академические исследования в современной науке, 4(23), 25-28.
19.
Bobosharipov, F., & Nadirova, Y. (2025). ЛАПАРОСКОПИК УСУЛДА
ГАСТРОДУОДЕНАЛ ЯРАЛАРНИНГ ПЕРФОРАЦИЯСИНИ ТИКИШ. Наука и
инновация, 3(14), 4-6.
20.
Надирова, Ю. (2024). ЭФФЕКТИВНОСТЬ ПРИМЕНЕНИЯ СТАТИНОВ
ПРИ
ЛЕЧЕНИИ
ОСТЕОПОРОЗА.
Академические
исследования
в
современной науке, 3(46), 96-100.
21.
Исмоилов, И. М., Надирова, Ю. И., Рахматуллаева, Н. Т., Мадазимова, Д.
Х., & Назарова, Н. О. (2020). АГРЕГАЦИОННАЯ ФУНКЦИЯ ТРОМБОЦИТОВ
ПРИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ. Студенческий вестник, (24-
2), 65-66.
22.
Аьзамхонов, А. А., Насриддинова, Н. Н., Максудова, М. Х., & Надирова,
Ю. И. (2020). ИЗУЧЕНИЕ АСПЕКТОВ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА,
ОСЛОЖНЕННОЙ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ.
Студенческий вестник, (3-2), 66-67.
23.
Абдунабиев, Х. А., Насриддинова, Н. Н., Максудова, М. Х., & Надирова,
Ю. И. (2020). ЭФФЕКТИВНОСТЬ САКУБИТРИЛ/ВАЛСАРТАНА У БОЛЬНЫХ
МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ
АКАДЕМИЧЕСКИХ НАУК
174
ГИПЕРТОНИЧЕСКОЙ
БОЛЕЗНЬЮ,
ОСЛОЖНЕННОЙ
ХРОНИЧЕСКОЙ
СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ. Студенческий вестник, (3-2), 64-65.
24.
Каримов, А. А., Сайдалиев, Р. С., & Надирова, Ю. И. (2020). ВЛИЯНИЯ
ПРИМЕНЕНИЯ
САКУБИТРИЛ/ВАЛСАРТАН
У
БОЛЬНЫХ
ХСН.
In
ИННОВАЦИОННЫЕ ПОДХОДЫ В СОВРЕМЕННОЙ НАУКЕ (pp. 14-18).
25.
Nadirova, Y. I., Jabbarov, O. O., & Bobosharipov, F. G. CARDIAC AND RENAL
DISEASES OFTEN COEXIST AND PATIENTS WITH CARDIAC AND RENAL
FAILURE HAVE HIGH MORBIDITY.
